Previous 10 | Next 10 |
COLLEGE STATION, TX / ACCESSWIRE / May 16, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com/ ). Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced that the Company's wholly owned subsidiary, Virogentics (VIRO), has received the analysis repo...
COLLEGE STATION, TX / ACCESSWIRE / December 13, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com/ ). Enzolytics' focus is on the production and distribution of the Company's therapeutics and advancing its research and development programs. The Company sees the coming year as a t...
COLLEGE STATION, TX / ACCESSWIRE / December 1, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com/ ). World AIDS Day has been recognized on this day since 1988. It is an important day for the world to reflect on those who have been lost in the HIV pandemic and recommit to the chal...
COLLEGE STATION, TX / ACCESSWIRE / November 16, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com/ ). Enzolytics, Inc. is a drug development company committed to the commercialization of its multiple proprietary therapeutics for the treatment of debilitating infectious diseas...
Summary Today, we circle back on Twist Bioscience Corporation for the first time since Spring of this year. This unique biology company is delivering stellar sales growth but continues to have significant cash burn issues despite a rock solid balance sheet. An investment analy...
COLLEGE STATION, TX / ACCESSWIRE / October 5, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ("ENZC" or the "Company"). The Company announces the completion of the first phase of the animal toxicology studies on its ITV-1 anti-HIV therapeutic. The initial toxicology study showed "no adverse effects...
COLLEGE STATION, TX / ACCESSWIRE / September 16, 2022 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company"). Enzolytics, Inc. announces a collaboration with Abveris, a division of Twist Bioscience Corporation, to discover fully human monoclonal antibodies against multiple viruses. Abveri...
Enzolytics, Inc. ( OTCPK:ENZC ), a drug developer focused on infectious diseases, announced Wednesday that a federal judge in Delaware dismissed a lawsuit filed by one of its shareholders requiring the company to replace 10M shares allegedly stolen by third parties. In respons...
COLLEGE STATION, TX / ACCESSWIRE / September 14, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) or the "Company" announces the successful conclusion, in a Delaware Federal litigation, 21-CV-01163-RGA, brought by Peter Mergenthaler against Enzolytics. Enzolytics' Motion to Dismiss was granted by the...
COLLEGE STATION, TX / ACCESSWIRE / July 28, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ("ENZC" or the "Company"). In the first Official Action on the Company's International Patent Application covering its discovery and exclusive claim to conserved antigens and epitopes of the HIV virus, the PC...
News, Short Squeeze, Breakout and More Instantly...
ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ( enzolytics.com ) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam Acquisition Corp ("SAGA") in its campaign to stop another attempt by NIKA Pharmaceutical and i...
BAYTOWN, TX, July 25, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp (Expert Market: SAGA) (the “Company”) announced today that it believes that a misleading press release has been issued by Nika Pharmaceuticals, Inc. in another attempt by NIKA and its CEO, Dimtar Savov, to fa...
Update on Sagaliam Acquisition Corp. ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (" enzolytics.com ") (the "Company") announced today that the Company is entering into a worldwide exclusive licensing agreement for US Patent # 8067531-B2, "Inactivated pepsin frag...